Skip to main content
Premium Trial:

Request an Annual Quote

PerkinElmer Q2 Profit Declines 15 Percent on 2.5-Percent Revenue Growth

This article has been updated to correct the change in PerkinElmer's net income, which declined to $24.5 million, not by $24.5 million.

NEW YORK (GenomeWeb News) – PerkinElmer today said second-quarter net income declined 15 percent as revenues inched up 2.5 percent.
 
Receipts for the three months ended July 2 increased to $377 million from $368 million year over year.
 
Revenue from the Life and Analytical Sciences segment increased 3 percent to $278.5 million from $270.8 million year over year. The genetic screening and service businesses contributed to the increase, the company said in a statement.
 
Revenue for the Optoelectronics segment remained essentially flat, at $98.5 million compared to $97 million from the same period last year.
 
R&D costs increased 13 percent to $25 million from $22 million from the comparable quarter a year ago.
 
PerkinElmer also reported a decline in net income to $24.5 million for the second quarter compared to $29 million last year.
 
PerkinElmer had $324 million in cash and cash equivalents as of July 2.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.